A Phase II Trial of Adjuvant Mitoxantrone (NSC #301739) for High Risk Patients Following Radical Prostatectomy
OBJECTIVES: I. Assess the feasibility of enrolling patients with adenocarcinoma of the
prostate at high risk for recurrence following radical prostatectomy in an adjuvant
mitoxantrone trial. II. Determine if this adjuvant therapy results in a delay in time to
failure or a decrease in the number of treatment failures compared to historical controls in
this patient population.
OUTLINE: Patients receive mitoxantrone IV over 10-30 minutes every 21 days. Treatment
continues for a maximum of 6 courses in the absence of unacceptable toxicity or disease
progression. Patients are followed every 3 months for the first 3 years, and then every 6
months for the next 3 years or until disease progression.
PROJECTED ACCRUAL: Approximately 60 patients will be accrued for this study over 18 months.
Interventional
Primary Purpose: Treatment
Joseph C. Presti, MD
Study Chair
Stanford University
United States: Federal Government
CDR0000067021
NCT00003858
Name | Location |
---|